株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

リキッドバイオプシー研究ツール・サービス・診断:世界市場

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

発行 BCC Research 商品コード 350412
出版日 ページ情報 英文 282 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
リキッドバイオプシー研究ツール・サービス・診断:世界市場 Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
出版日: 2017年10月01日 ページ情報: 英文 282 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のリキッドバイオプシー (液体生検) 市場は、2017年の15億米ドルから、2022年までに45億米ドルまで拡大すると見られています。市場は、2017年〜2022年のCAGR (複合年間成長率) で、24.2%の成長が予測されています。

当レポートでは、世界のリキッドバイオプシー研究ツール・サービス・診断市場について調査分析し、市場概要、市場動向分析と予測、技術の背景、セグメント別の市場分析、市場力学、主要企業プロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 サマリーとハイライト

第3章 概要

  • イントロダクション
  • 調査範囲
  • リキッドバイオプシー vs. 従来型バイオプシー
  • 市場
  • 成長促進要因
  • 主要動向
  • 産業

第4章 技術の背景

  • リキッドバイオプシーバイオマーカー
  • 癌ゲノミクス
  • 非侵襲出生前検診
  • 循環腫瘍細胞 (CTC) 技術
  • CTCワークフロー
  • 細胞単離技術
  • CTCサンプル調製技術
  • CTCダウンストリーム分析技術
  • リキッドバイオプシーと従来型バイオプシーとの比較
    • 癌検査
    • 出生前検診

第5章 リキッドバイオプシーのイニシアチブ

第6章 リキッドバイオプシー応用

  • イントロダクション
  • 癌応用
  • リプロダクティブヘルス応用
  • 移植診断応用

第7章 リキッドバイオプシー産業

  • イントロダクション
  • NGS装置産業
  • 第3世代シークエンシング産業
  • ドロップレットデジタルPCR (DDPCR) 産業
  • ターゲットエンリッチメント・調整産業
  • 単細胞DNAポリメラーゼ産業
  • 非侵襲出生前検診産業
  • 胎児細胞NIPT産業
  • CTC採取・検出産業
  • リキッドバイオプシー産業
  • D2C遺伝子検査産業

第8章 買収と戦略的アライアンス

  • 買収
  • 戦略的アライアンス

第9章 リキッドバイオプシー市場

  • 成長促進要因
  • リキッドバイオプシー市場:適応別
  • リキッドバイオプシー市場:バイオマーカータイプ別
  • リキッドバイオプシー市場:解析プラットフォーム別
  • リキッドバイオプシー市場:解析目的別
  • 非侵襲出生前検診市場
  • 癌市場
  • 移植市場
  • 地域別市場

第10章 特許分析

  • CTC特許
  • 問題点

第11章 企業プロファイル

BCC Researchについて

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO150B

Report Highlights

The global liquid biopsy market should reach $4.5 billion by 2022 from $1.5 billion in 2017 at a compound annual growth rate (CAGR) of 24.2%, from 2017 to 2022.

Report Includes:

  • An overview of the global markets for liquid biopsy research tools, services, and diagnostics
  • Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Coverage of how these technologies can reduce invasive tumor biopsies, drive early cancer detection, and support precise drug administration
  • Detailed analysis of liquid biopsy workflow technologies, biomarker classes, sample types, and research tools reagents
  • Breakdowns of the market by product, product type, application, end use industry, technology, and indication
  • Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
  • Profiles of major players in the industry

Report Scope

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies.The market sizes for liquid biopsy diagnostics are given for the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy.It then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development.Market driving forces are also discussed.

The structure of several important industry subsectors is reviewed, as well as major industry acquisitions and strategic alliances from January 2016 through July 2017.Industry subsectors analyzed includenext-generation sequencing(NGS) instruments, droplet digital PCR, target enrichment and amplification, single-cell DNA polymerase, prenatal screening, liquid biopsy, direct to consumer, and clinical laboratory.

The market for liquid biopsy diagnostics is analyzed in depth.The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and other), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia-Pacific, Rest of World).

Market data cover the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

More than 165 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2016 through July 2017, including key alliance trends.

Analyst Credentials

John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Overview

  • Introduction
  • Report Scope
  • Liquid Biopsy versus Traditional Biopsy
  • Markets
  • Growth Driving Forces
  • Key Trends
  • Industry

Chapter 4: Technology Background

  • Liquid Biopsy Biomarkers
  • Cancer Genomics
  • Noninvasive Prenatal Testing
  • Circulating Tumor Cell Technologies
  • CTC Workflow
  • Cell Isolation Technologies
  • CTC Sample Preparation Technologies
  • CTC Downstream Analysis Technologies
  • Comparison of Liquid Biopsy with Conventional Biopsy
    • Cancer Testing
    • Prenatal Testing

Chapter 5: Liquid Biopsy Initiatives

  • Blood Profiling Atlas
  • Cambridge Single Cell Analysis Core Facility
  • Cancer-ID
  • CTCTrap Consortium
  • Early Cancer Detection Consortium
  • Hematologic Oncology Consortium
  • National Center for Single-Cell Biology
  • Precancer Genome Atlas
  • Precision Medicine Initiative
  • Single Cell Analysis Program
  • TopMed
  • Worldwide Innovative Networking (WIN) Consortium

Chapter 6: Liquid Biopsy Applications

  • Introduction
  • Cancer Applications
    • Precision Medicine
    • Cancer Biomarker Status
    • Cancer Market Segments
  • Reproductive Health Applications
  • Transplant Diagnostics Applications

Chapter 7: Liquid Biopsy Industry

  • Introduction
  • NGS Instrument Industry
  • Third-Generation Sequencing Industry
  • Droplet Digital PCR Industry
  • Target Enrichment and Amplification Industry
  • Single-Cell DNA Polymerase Industry
  • NGS Clinical Informatics Industry
  • Testing Services Industry
  • Noninvasive Prenatal Testing Industry
  • Fetal Cell NIPT Industry
  • CTC Capture and Detection Industry
  • Liquid Biopsy Industry
  • Direct-to-Consumer Genetic Testing Industry

Chapter 8: Acquisitions and Strategic Alliances

  • Acquisitions
  • Strategic Alliances
    • Trends
    • 2016 Alliances
    • 2017 Alliances

Chapter 9: Liquid Biopsy Markets

  • Growth Driving Forces
  • Liquid Biopsy Market by Indication
  • Liquid Biopsy Market by Biomarker Type
  • Liquid Biopsy Market by Analysis Platform
  • Liquid Biopsy Market by Analysis Purpose
  • Noninvasive Prenatal Testing Market
  • Cancer Markets
    • Cancer Market by Indication
    • Cancer Market by Analysis Purpose
    • Cancer Market by Biomarker Class
    • Cancer Market by Analysis Method
    • Breast Cancer Market
    • Colorectal Cancer Market
    • Hematological Cancer Market
    • Lung Cancer Market
    • Pan-Cancer Market
  • Transplant Markets
  • Geographical Market

Chapter 10: Patent Review

  • Circulating Tumor Cell Patents
    • Cell-Free DNA Patents
  • Liquid Biopsy- and Sequencing-Related Patent Issues

Chapter 11: Company Profiles

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table: Global Liquid Biopsy Market, by Disease Class, Through 2022 ($ Millions)
    • Table 1: Liquid Biopsy Sample Types
    • Table 2: Liquid Biopsy Report Scope
    • Table 3: Global Liquid Biopsy Market, by Analysis Type, Through 2022 ($ Millions)
    • Table 4: Growth Driving Forces
    • Table 5: Key Trends in Liquid Biopsy Market
    • Table 6: Liquid Biopsy Industry Subsectors
    • Table 7: Liquid Biopsy Biomarker Classes
    • Table 8: Single-Cell Analysis to Identify Cancer Driver Mutations
    • Table 9: Genomics-Based Oncology Workflow
    • Table 10: Unique Challenges of CTC Capture and Analysis
    • Table 11: CTC Workflow
    • Table 12: Cell Differentiators
    • Table 13: Cell Isolation Technologies
    • Table 14: CTC Sample Preparation Technologies
    • Table 15: Single-Cell Analysis Technologies
    • Table 16: Estimated Annual Solid Biopsy Procedures Performed in the U.S. for Selected Cancers
    • Table 17: Main Risks for Needle-Based Tissue Biopsies
    • Table 18: Factors in Tissue Biopsy
    • Table 19: Prenatal Invasive Testing Technologies
    • Table 20: Invasive versus Noninvasive Prenatal Technologies
    • Table 21: Key Liquid Biopsy Research and Development Programs
    • Table 22: Source of Foreign Biomarkers for Liquid Biopsy Applications
    • Table 23: Personalized Medicine Driven by Cancer Common Genetic Mutations
    • Table 24: Cancer Liquid Biopsy Biomarker Clinical Status
    • Table 25: Cancer Liquid Biopsy Market Segments
    • Table 26: Reproductive Health Screening Application
    • Table 27: Ethical Issues Associated with NIPT
    • Table 28: Transplant Diagnostics Application
    • Table 29: Key Segments within the Liquid Biopsy Industry
    • Table 30: Next-Generation Sequencing Instrument Companies
    • Table 31: 3GS Industry, by Tier Status
    • Table 32: Advantages of Droplet Digital PCR for Single-Cell Analysis
    • Table 33: Droplet Digital PCR Industry
    • Table 34: Target Enrichment Industry
    • Table 35: Single-Cell DNA Polymerase Industry
    • Table 36: Next-Generation Sequencing Clinical Informatics Company Positioning
    • Table 37: Selected NGS Clinical Testing Laboratories
    • Table 38: NIPT Industry
    • Table 39: Global Market Share for NIPT, by Company and by Region, 2017
    • Table 40: German NGS-based Noninvasive Prenatal Diagnostic Companies, 2017
    • Table 41: NIPT Test Licensing, by Country
    • Table 42: Fetal Cell NIPT Industry
    • Table 43: CTC Capture and Detection Industry
    • Table 44: Liquid Biopsy Industry Company Focus
    • Table 45: Example of NGS-based Liquid Biopsy Market Differentiation
    • Table 46: Key Competitors in the Direct-to-Consumer Genetic Testing Industry
    • Table 47: Liquid Biopsy Industry Acquisitions, January 2016-July 2017
    • Table 48: Liquid Biopsy Strategic Alliances, January 2016-July 2017
    • Table 49: Liquid Biopsy Key Growth Driving Forces
    • Table 50: Global Liquid Biopsy Market, by Indication, Through 2022 ($ Millions)
    • Table 51: Global Liquid Biopsy Market, by Biomarker Type, Through 2022 ($ Millions)
    • Table 52: Global Liquid Biopsy Market, by Analysis Platform, Through 2022 ($ Millions)
    • Table 53: Global Liquid Biopsy Market, by Analysis Purpose, Through 2022 ($ Millions)
    • Table 54: Global NIPT Market, by Analysis Purpose, Through 2022 ($ Millions)
    • Table 55: Global NIPT Market, by Risk Type, Through 2022 ($ Millions)
    • Table 56: Global NIPT Market, by Biomarker Class, Through 2022 ($ Millions)
    • Table 57: Global NIPT Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 58: Limitations of Solid Biopsy in Cancer Applications
    • Table 59: Global Cancer Market, by Indication, Through 2022 ($ Millions)
    • Table 60: Five-Year Survival Rate for Ovarian Cancer (%)
    • Table 61: Prostate Cancer Testing Industry
    • Table 62: Molecular Thyroid Nodule Classifier Test Company Positioning
    • Table 63: Global Cancer Market, by Analysis Purpose, Through 2022 ($ Millions)
    • Table 64: Cancer Detection Methods
    • Table 65: Early Detection Tissue of Origin Approaches
    • Table 66: NGS Instrument Company Companion Diagnostics Status
    • Table 67: Global Cancer Market, by Biomarker Class, Through 2022 ($ Millions)
    • Table 68: Global Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 69: Global Breast Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 70: Global Colorectal Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 71: Global Hematological Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 72: Global Lung Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 73: Global Pan-Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 74: Global Liquid Biopsy Transplant Market, by Analysis Purpose, Through 2022 ($ Millions)
    • Table 75: Global Liquid Biopsy Transplant Market, by Organ Type, Through 2022 ($ Millions)
    • Table 76: Transplant Procedures Performed in the U.S., 2015 and 2016
    • Table 77: Global Liquid Biopsy Transplant Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 78: Global Liquid Biopsy Transplant Market, by Biomarker Class, Through 2022 ($ Millions)
    • Table 79: Global Liquid Biopsy Market, by Region, Through 2022 ($ Millions)
    • Table 80: Global Cancer Liquid Biopsy Market, by Region, Through 2022 ($ Millions)
    • Table 81: Global NIPT Market, by Region, Through 2022 ($ Millions)
    • Table 82: Global Transplant Market, by Region, Through 2022 ($ Millions)
    • Table 83: CTC-Related Patents, by Region, 2007-2017
    • Table 84: Cell-Free DNA-Related Patents, by Region, 2007-2017
    • Table 85: Status of Liquid Biopsy and Sequencing-Related Patent Disputes
    • Table 86: Sensitivity to Detect Drug-resistant Mutations in Viruses (%)

List of Figures

  • Summary Figure: Global Liquid Biopsy Market, by Disease Class, 2015-2022 ($ Millions)
    • Figure 1: How Cancer Genomics Drives Liquid Biopsy
Back to Top